<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32253508</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>267</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Diaphragmatic CMAP amplitude from phrenic nerve stimulation predicts functional decline in ALS.</ArticleTitle><Pagination><StartPage>2123</StartPage><EndPage>2129</EndPage><MedlinePgn>2123-2129</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-020-09818-z</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To evaluate phrenic nerve motor amplitude (PhrenicAmp) as an independent predictor of functional decline in amyotrophic lateral sclerosis (ALS). We also assessed both PhrenicAmp and forced vital capacity (FVC) as predictors of functional loss in patients with bulbar dysfunction.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We included consecutive ALS patients with PhrenicAmp and FVC at baseline. Participants were evaluated with the revised ALS Functional Rating Scale (ALSFRS-R) at inclusion and at, at least, one subsequent follow-up visit. The outcome measure of functional decline was the percentage reduction in ALSFRS-R from baseline. Bulbar dysfunction was defined by the presence of any relevant symptom on the ALSFRS-R bulbar sub-score. Correlations and mixed-effects regressions were used to study the relationship between functional decline and both PhrenicAmp and FVC baseline evaluations.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 249 ALS patients were included; 64.2% of these had bulbar dysfunction. At inclusion, significant correlations were found between PhrenicAmp and FVC (p&#x2009;&lt;&#x2009;0.001), as well as between each respiratory measure and ALSFRS-R (all p&#x2009;&lt;&#x2009;0.001). The functional decline at first (median 3&#xa0;months) and second (median 6&#xa0;months) follow-up visits was significantly correlated with baseline values of both respiratory evaluations (all p&#x2009;&lt;&#x2009;0.01) in the entire ALS population, but only with baseline PhrenicAmp (all p&#x2009;&lt;&#x2009;0.05) in bulbar dysfunction cases. Regression analysis revealed that PhrenicAmp (all p&#x2009;&lt;&#x2009;0.05), but not FVC, was a significant independent predictor of functional decline in ALS patients and in those with bulbar dysfunction.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Baseline PhrenicAmp is an independent predictor of functional decline in ALS, whether or not bulbar dysfunction is present.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miranda</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0003-4660-6051</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences and Mental Health, Hospital de Santa Maria-CHLN, Lisbon, Portugal. bruno.a.miranda@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Medicina Molecular, Translational Clinical Physiology, Universidade de Lisboa, Lisbon, Portugal. bruno.a.miranda@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Fisiologia, Universidade de Lisboa, Av. Professor Egas Moniz, 1649-028, Lisbon, Portugal. bruno.a.miranda@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gromicho</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2111-4579</Identifier><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Medicina Molecular, Translational Clinical Physiology, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-1574-6476</Identifier><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Medicina Molecular, Translational Clinical Physiology, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Susana</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0727-5897</Identifier><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Medicina Molecular, Translational Clinical Physiology, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swash</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8717-8914</Identifier><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Medicina Molecular, Translational Clinical Physiology, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Mamede</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7556-0158</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences and Mental Health, Hospital de Santa Maria-CHLN, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Medicina Molecular, Translational Clinical Physiology, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculdade de Medicina, Instituto de Fisiologia, Universidade de Lisboa, Av. Professor Egas Moniz, 1649-028, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PTDC/MEC-NEU/31195/2017</GrantID><Agency>Funda&#xe7;&#xe3;o para a Ci&#xea;ncia e a Tecnologia</Agency><Country/></Grant><Grant><GrantID>Pr&#xe9;mio Jo&#xe3;o Lobo Antunes 2017</GrantID><Agency>Santa Casa da Miseric&#xf3;rdia de Lisboa</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000200" MajorTopicYN="N">Action Potentials</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003680" MajorTopicYN="N">Deglutition Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003964" MajorTopicYN="N">Diaphragm</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010791" MajorTopicYN="N">Phrenic Nerve</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012466" MajorTopicYN="N">Salivary Gland Diseases</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013064" MajorTopicYN="N">Speech Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Diaphragm</Keyword><Keyword MajorTopicYN="N">Forced vital capacity</Keyword><Keyword MajorTopicYN="N">Functional decline</Keyword><Keyword MajorTopicYN="N">Phrenic nerve motor response</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32253508</ArticleId><ArticleId IdType="doi">10.1007/s00415-020-09818-z</ArticleId><ArticleId IdType="pii">10.1007/s00415-020-09818-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O et al (2011) Amyotrophic lateral sclerosis. Lancet 377:942&#x2013;955</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61156-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E et al (2009) Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 10:310&#x2013;323</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960802566824</ArticleId></ArticleIdList></Reference><Reference><Citation>Creemers H, Grupstra H, Nollet F, van den Berg LH, Beelen A (2014) Prognostic factors for the course of functional status of patients with ALS: a systematic review. J Neurol 262:1407&#x2013;1423</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-014-7564-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowser R, Turner MR, Shefner J (2011) Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations. Nat Rev Neurol 7:631&#x2013;638</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2011.151</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon NG, Turner MR, Vucic S, Al-Chalabi A, Shefner J, Lomen-Hoerth C et al (2014) Quantifying disease progression in amyotrophic lateral sclerosis. Ann Neurol 76:643&#x2013;657</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24273</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA et al (2013) The combined assessment of function and survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener 14:162&#x2013;168</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2012.762930</ArticleId></ArticleIdList></Reference><Reference><Citation>Tramacere I, Dalla Bella E, Chio A, Mora G, Filippini G, Lauria G et al (2015) The MITOS system predicts long-term survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 86:1180&#x2013;1185</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2014-310176</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR (2016) The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener 17:414&#x2013;425</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1140786</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg LH, Sorensen E, Gronseth G et al (2019) Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology 92:e1610&#x2013;e1623</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007242</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B et al (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169:13&#x2013;21</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV (2002) Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 25:709&#x2013;714</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.10090</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH et al (2005) The ALSFRS-R predicts survival time in an ALS clinic population. Neurology 64:38&#x2013;43</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000148648.38313.64</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H et al (2006) Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 66:265&#x2013;267</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000194316.91908.8a</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Pradat PF, Salachas F, Bruneteau G, Le Forestier N, Seilhean D et al (2008) Causes of death in a post-mortem series of ALS patients. Amyotroph Lateral Scler 9:59&#x2013;62</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701656940</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W et al (2009) Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 73:1218&#x2013;1226</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181bc0141</ArticleId></ArticleIdList></Reference><Reference><Citation>EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis, Andersen PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Van Damme P et al (2012) EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)&#x2014;revised report of an EFNS task force. Eur J Neurol 19:360&#x2013;375</Citation></Reference><Reference><Citation>Fallat RJ, Jewitt B, Bass M, Kamm B, Norris F (1979) Spirometry in amyotrophic lateral sclerosis. Arch Neurol 36:74&#x2013;80</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1979.00500380044004</ArticleId></ArticleIdList></Reference><Reference><Citation>Traynor BJ, Zhang H, Shefner JM, Schoenfeld D, Cudkowicz ME (2004) Functional outcome measures as clinical trial endpoints in ALS. Neurology 63:1933&#x2013;1935</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000144345.49510.4E</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann F, Henderson RD, Morrison SC, Brown M, Hutchinson N, Douglas JA et al (2010) Use of respiratory function tests to predict survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 11:194&#x2013;202</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482960902991773</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiffman PL, Belsh JM (1993) Pulmonary function at diagnosis of amyotrophic lateral sclerosis: rate of deterioration. Chest 103:508&#x2013;513</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.103.2.508</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaplinski A, Yen AA, Appel SH (2006) Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry 77:390&#x2013;392</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.072660</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE et al (2018) Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol 17:423&#x2013;433</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M (2014) Breathing new life into treatment advances for respiratory failure in amyotrophic lateral sclerosis patients. Neurodegener Dis Manag 4:83&#x2013;102</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/nmt.13.74</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, Pinto A, Atalaia A, Peralta R, De Carvalho M (2007) Respiratory apraxia in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 8:180&#x2013;184</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960701249340</ArticleId></ArticleIdList></Reference><Reference><Citation>Evangelista T, de Carvalho M, Pinto A, Sales-Luis ML (1995) Phrenic nerve conduction in amyotrophic lateral sclerosis. J Neurol Sci 129:35&#x2013;37</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(95)00057-9</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Pinto S, Swash M (2018) Diaphragm motor responses to phrenic nerve stimulation in ALS: surface and needle recordings. Clin Neurophysiol 129:349&#x2013;353</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2017.11.019</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, Geraldes R, Vaz N, Pinto A, de Carvalho M (2009) Changes of the phrenic nerve motor response in amyotrophic lateral sclerosis: longitudinal study. Clin Neurophysiol 120:2082&#x2013;2085</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2009.08.025</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, Pinto A, de Carvalho M (2012) Phrenic nerve studies predict survival in amyotrophic lateral sclerosis. Clin Neurophysiol 123:2454&#x2013;2459</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2012.05.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, Turkman A, Pinto A, Swash M, de Carvalho M (2009) Predicting respiratory insufficiency in amyotrophic lateral sclerosis: the role of phrenic nerve studies. Clin Neurophysiol 120:941&#x2013;946</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2009.02.170</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Swash M, Pinto S (2019) Diaphragmatic neurophysiology and respiratory markers in ALS. Front Neurol 10:143</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00143</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1:293&#x2013;299</Citation></Reference><Reference><Citation>de Carvalho M, Dengler R, Eisen A, England JD, Kaji R, Kimura J et al (2008) Electrodiagnostic criteria for diagnosis of ALS. Clin Neurophysiol 119:497&#x2013;503</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2007.09.143</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M (2010) Symmetry of phrenic nerve motor response in amyotrophic lateral sclerosis. Muscle Nerve 42:882&#x2013;884</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21816</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M (2017) Comparison of slow and forced vital capacities on ability to predict survival in ALS. Amyotroph Lateral Scler Frontotemporal Degener 18:528&#x2013;533</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1354995</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, Itoyama Y, Sobue G, Togo M et al (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16:505&#x2013;512</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Calvo A, Vasta R, Moglia C et al (2020) Prognostic role of slow vital capacity in amyotrophic lateral sclerosis. J Neurol. https://doi.org/10.1007/s00415-020-09751-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09751-1</ArticleId><ArticleId IdType="pubmed">32556567</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J (2001) Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 124:2000&#x2013;2013</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/124.10.2000</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrieri MC, Miranda B, Gromicho M, Pinto S, de Carvalho M (2020) Reliability of phrenic nerve conduction study: In healthy controls and in patients with primary lateral sclerosis. Clin Neurophysiol 131:994&#x2013;999</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2020.02.010</ArticleId></ArticleIdList></Reference><Reference><Citation>de Carvalho M, Chio A, Dengler R, Hecht M, Weber M, Swash M (2005) Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. Amyotroph Lateral Scler 6:17&#x2013;28</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820410020600</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B, Wei Q, Ou R, Zhang L, Hou Y, Chen Y, Shang H (2019) Neurophysiological index is associated with the survival of patients with amyotrophic lateral sclerosis. Clin Neurophysiol. https://doi.org/10.1016/j.clinph.2019.05.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2019.05.012</ArticleId><ArticleId IdType="pubmed">31751840</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>